[HTML][HTML] Two phase 3 trials of gantenerumab in early Alzheimer's disease
RJ Bateman, J Smith, MC Donohue… - … England Journal of …, 2023 - Mass Medical Soc
Background Monoclonal antibodies that target amyloid-beta (Aβ) have the potential to slow
cognitive and functional decline in persons with early Alzheimer's disease. Gantenerumab is …
cognitive and functional decline in persons with early Alzheimer's disease. Gantenerumab is …
The single toxin origin of Alzheimer's disease and other neurodegenerative disorders enables targeted approach to treatment and prevention
M Tolar, JA Hey, A Power, S Abushakra - International Journal of …, 2024 - mdpi.com
New data suggest that the aggregation of misfolded native proteins initiates and drives the
pathogenic cascade that leads to Alzheimer's disease (AD) and other age-related …
pathogenic cascade that leads to Alzheimer's disease (AD) and other age-related …
Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer's disease
Clinical management and therapeutics development for Alzheimer's disease (AD) have
entered a new era, with recent approvals of monoclonal antibody therapies targeting the …
entered a new era, with recent approvals of monoclonal antibody therapies targeting the …
Plasma p‐tau immunoassays in clinical research for Alzheimer's disease
CE Teunissen, R Kolster, G Triana‐Baltzer… - Alzheimer's & … - Wiley Online Library
The revised biomarker framework for diagnosis and staging of Alzheimer's disease (AD)
relies on amyloid beta (Aβ) and tau pathologies as core markers, and markers for adjacent …
relies on amyloid beta (Aβ) and tau pathologies as core markers, and markers for adjacent …